GO:0047638 albendazole monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047638 (albendazole monooxygenase activity) catalyzes the NADPH- and O2-dependent S-oxidation of albendazole to albendazole S-oxide, a key activation step in benzimidazole anthelmintic metabolism.
• The reaction consumes H+, NADPH and O2 and produces albendazole S-oxide, H2O and NADP+, classifying the activity as a monooxygenase (EC 1.14.13.-).
• Cytochrome P450 enzymes, particularly CYP3A4, are the principal catalysts of this sulfoxidation reaction in human liver and intestinal models.
• CYP3A4 expression and activity are regulated transcriptionally (e.g., by PXR and METTL3-dependent mRNA stabilization) and post-translationally (e.g., heme loading modulated by nitric oxide).
• Inter-individual variability in CYP3A4 activity, driven by drug-drug interactions and genetic polymorphisms, can alter albendazole sulfoxidation and therapeutic outcomes.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of candidate monooxygenases in albendazole metabolism and resistance.
Description
Albendazole monooxygenase activity (GO:0047638) is a molecular function defined by the catalytic conversion of albendazole to albendazole S-oxide, a reaction that requires NADPH, H+ and O2 and yields H2O and NADP+ as co-products. This oxidative transformation is the first and rate-limiting step in the metabolic activation of albendazole, a broad-spectrum benzimidazole anthelmintic used against soil-transmitted helminths and cystic echinococcosis. Because albendazole S-oxide retains anthelmintic activity, the monooxygenase step is pharmacologically productive rather than purely detoxifying, making it a focal point for understanding drug efficacy and resistance. The enzymatic activity is attributed predominantly to cytochrome P450 monooxygenases, especially CYP3A4, which is abundantly expressed in liver and intestine and exhibits broad substrate promiscuity. CYP3A4-mediated sulfoxidation of albendazole is influenced by co-administered drugs, dietary compounds and endogenous modulators that alter heme loading or enzyme expression. Consequently, GO:0047638 sits at the intersection of anthelmintic pharmacology, drug-drug interaction science and personalized medicine. For researchers, GO:0047638 provides a precise functional annotation for genes and proteins that catalyze this specific sulfoxidation reaction. It enables comparative analyses across species, supports functional genomics of anthelmintic resistance, and guides the design of CRISPR-engineered cell models to test causality of candidate monooxygenases. This article synthesizes the QuickGO definition with verified literature to outline the mechanism, key genes, disease relevance and experimental strategies for studying albendazole monooxygenase activity.
albendazole monooxygenase activity At A Glance
| GO ID | GO:0047638 |
|---|---|
| GO term | albendazole monooxygenase activity |
| Ontology | molecular_function |
| Synonym | albendazole,NADPH:oxygen oxidoreductase (sulfoxide-forming); albendazole oxidase activity; albendazole sulfoxidase activity |
| Definition | Catalysis of the reaction: albendazole + H+ + NADPH + O2 = albendazole S-oxide + H2O + NADP+. |
| Major function | Oxidative activation of albendazole to its active S-oxide metabolite via sulfoxidation. |
| Cofactors | NADPH and molecular oxygen; proton required. |
| Representative enzymes | Cytochrome P450 monooxygenases, notably CYP3A4. |
| Pathway context | Xenobiotic metabolism; benzimidazole anthelmintic activation. |
What Is GO:0047638?
In our own words, GO:0047638 describes the catalytic activity of an enzyme that uses molecular oxygen and NADPH to insert one oxygen atom into albendazole, forming albendazole S-oxide while releasing water and NADP+. The reaction requires a proton and is classified as a monooxygenase (sulfoxide-forming) activity. This definition captures the exact stoichiometry and cofactor requirements specified by QuickGO, and it distinguishes the activity from other albendazole-metabolizing reactions such as hydrolysis or glucuronidation.
Why Is albendazole monooxygenase activity Important in Cell Biology?
GO:0047638 is important because it defines the biochemical step that converts albendazole into its pharmacologically active S-oxide metabolite, directly influencing anthelmintic efficacy and resistance. The activity is mediated primarily by CYP3A4, an enzyme notorious for drug-drug interactions and inter-individual variability, so understanding this function is essential for predicting therapeutic outcomes and optimizing dosing. Moreover, the term provides a functional annotation that can be used to identify and validate candidate genes in parasitic and host genomes, supporting drug discovery and resistance monitoring.
• Defines the rate-limiting activation step of albendazole, a WHO-listed essential anthelmintic.
• Enables functional annotation of cytochrome P450 genes involved in benzimidazole metabolism.
• Supports prediction of drug-drug interactions that alter albendazole efficacy.
• Provides a mechanistic basis for inter-individual variability in anthelmintic response.
• Facilitates comparative genomics of anthelmintic resistance in parasites.
• Guides CRISPR-based validation of candidate monooxygenases in cell and animal models.
• Links xenobiotic metabolism to heme availability and post-translational regulation.
• Informs personalized therapy in cancer patients receiving CYP3A4-metabolized drugs.
• Supports pharmacokinetic modeling of benzimidazole drugs.
• Enables high-throughput screening for enzyme inhibitors or enhancers.
Molecular Mechanism of albendazole monooxygenase activity
Substrate binding and orientation
In simple terms: The enzyme grabs albendazole and positions it so that oxygen can be added at the sulfur atom.
Cytochrome P450 enzymes such as CYP3A4 bind albendazole within a hydrophobic active site above the heme iron, orienting the benzimidazole sulfur toward the catalytic center. Substrate binding induces a low-spin to high-spin transition of the heme iron, facilitating subsequent electron transfer from NADPH via cytochrome P450 reductase. Structural studies of CYP3A4 reveal a large, flexible active cavity that accommodates diverse substrates, explaining its ability to oxidize albendazole.
Oxygen activation and electron transfer
In simple terms: The enzyme uses electrons from NADPH to split oxygen, creating a reactive species that can add to albendazole.
Following substrate binding, NADPH donates electrons through cytochrome P450 reductase to the heme iron, enabling O2 binding and cleavage. The resulting high-valent iron-oxo species (Compound I) abstracts an electron from the sulfur atom of albendazole, forming a transient radical that rebounds to yield albendazole S-oxide. This monooxygenase mechanism consumes one NADPH and one O2 per product formed, consistent with the GO:0047638 definition.
Product formation and release
In simple terms: The oxidized product, albendazole S-oxide, is released, and the enzyme returns to its resting state.
After oxygen insertion, albendazole S-oxide dissociates from the active site, and the heme iron returns to its ferric resting state, ready for another catalytic cycle. The S-oxide metabolite retains anthelmintic activity and can undergo further oxidation to the inactive sulfone, but the initial sulfoxidation is attributed to GO:0047638. Product release may be influenced by active-site residues and solvent access channels, as suggested by CYP3A4 structural analyses.
Cofactor and heme availability
In simple terms: The enzyme needs a heme cofactor and NADPH to work; anything that affects heme levels can change activity.
CYP3A4 is a heme-thiolate protein, and its catalytic activity depends on proper heme loading. Nitric oxide can modulate CYP2D6 and CYP3A4 activity in a concentration-dependent manner by affecting heme loading, thereby potentially influencing albendazole monooxygenase activity. Additionally, METTL3 regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA, which can alter the abundance of the enzyme available for albendazole sulfoxidation.
Regulation by drug interactions and genetic variation
In simple terms: Other drugs and genetic differences can speed up or slow down this enzyme, changing how well albendazole works.
CYP3A4 activity is subject to inhibition or induction by co-administered drugs, leading to drug-drug interactions that can alter albendazole pharmacokinetics. For example, a 5-lipoxygenase activating protein inhibitor was shown to affect the pharmacokinetics of oral midazolam, a CYP3A4 probe substrate, illustrating the potential for similar interactions with albendazole. Genetic polymorphisms in CYP3A4 and related genes contribute to inter-individual variability in monooxygenase activity, which may impact anthelmintic efficacy.
Key Genes Involved in GO:0047638 albendazole monooxygenase activity
The following genes and proteins are directly or indirectly implicated in albendazole monooxygenase activity (GO:0047638), based on their roles in cytochrome P450-mediated xenobiotic metabolism, heme biosynthesis, and regulatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP3A4 | Principal enzyme catalyzing albendazole S-oxidation | Target for knockout/knock-in to assess albendazole metabolism |
| CYP3A5 | Cytochrome P450 isoform with overlapping substrate specificity | Candidate modifier of albendazole sulfoxidation |
| CYP2D6 | Cytochrome P450 involved in xenobiotic oxidation, modulated by nitric oxide | Potential alternative monooxygenase for albendazole |
| POR | Cytochrome P450 oxidoreductase, transfers electrons from NADPH to CYP enzymes | Essential cofactor for reconstituting monooxygenase activity |
| NR1I2 (PXR) | Nuclear receptor regulating CYP3A4 transcription | Knockout models to study induction of albendazole metabolism |
| METTL3 | m6A methyltransferase regulating CYP3A4 mRNA stability and PXR translation | Epitranscriptomic regulator of monooxygenase expression |
| ALB | Albendazole is a substrate, not a gene; listed for context | Not applicable |
| FMO3 | Flavin-containing monooxygenase, potential alternative sulfoxidase | Comparative studies of sulfoxidation |
| GSTA1 | Glutathione S-transferase, involved in detoxification of albendazole metabolites | Modifies downstream metabolite fate |
| UGT1A1 | UDP-glucuronosyltransferase, conjugates albendazole metabolites | Affects overall drug clearance |
| ABCB1 | P-glycoprotein efflux transporter, affects albendazole availability | Modulates intracellular substrate concentration |
| HMOX1 | Heme oxygenase, regulates heme availability for CYP enzymes | Indirect regulator of monooxygenase activity |
| NQO1 | Quinone oxidoreductase, may influence redox state | Potential modifier of cofactor balance |
| KEAP1 | Regulator of NRF2-mediated antioxidant response | Indirect effect on xenobiotic metabolism genes |
| NFE2L2 (NRF2) | Transcription factor inducing phase I/II enzymes | Regulates CYP expression under stress |
| AHR | Aryl hydrocarbon receptor, induces CYP1A/1B | Cross-talk with CYP3A4 regulation |
| CAR (NR1I3) | Constitutive androstane receptor, regulates CYP genes | Alternative induction pathway for monooxygenases |
How Is albendazole monooxygenase activity Regulated?
Albendazole monooxygenase activity is regulated at multiple levels. Transcriptionally, CYP3A4 expression is induced by xenobiotics via nuclear receptors such as PXR, and this induction is modulated by METTL3-dependent m6A modification of CYP3A4 mRNA and PXR translation. Post-translationally, heme availability critically controls CYP3A4 activity, and nitric oxide can modulate heme loading in a concentration-dependent manner. Additionally, drug-drug interactions can inhibit or induce CYP3A4 activity, as exemplified by studies with a 5-lipoxygenase activating protein inhibitor affecting midazolam pharmacokinetics. These regulatory layers collectively determine the rate of albendazole S-oxidation in vivo.
albendazole monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP3A4 | Altered drug metabolism in cancer and infectious diseases | CYP3A4 knockout HepG2 cells for albendazole sulfoxidation assays |
| CYP3A4 | Drug-drug interactions affecting anthelmintic efficacy | CYP3A4-overexpressing Caco-2 cells for transport and metabolism studies |
| METTL3 | Epitranscriptomic regulation of CYP3A4 in drug metabolism | METTL3 knockout hepatocytes to assess CYP3A4 induction |
| HMOX1 | Heme availability and oxidative stress | HMOX1 knockout macrophages to study heme modulation of CYP3A4 |
| NR1I2 (PXR) | Induction of CYP3A4 by xenobiotics | PXR knockout mouse models for pharmacokinetic studies |
Anthelmintic efficacy and resistance
GO:0047638 is directly linked to the treatment of soil-transmitted helminthiases and cystic echinococcosis, where albendazole is a first-line therapy. Reduced monooxygenase activity could decrease formation of the active S-oxide metabolite, potentially lowering efficacy, while increased activity might enhance drug action but also accelerate clearance. In parasites, differences in monooxygenase expression or sequence may contribute to benzimidazole resistance, making this activity a marker for resistance monitoring.
Drug-drug interactions in polypharmacy
Because CYP3A4 mediates albendazole sulfoxidation, co-administration of CYP3A4 inhibitors or inducers can alter albendazole exposure and therapeutic outcomes. For example, a drug-drug interaction study with a 5-lipoxygenase activating protein inhibitor and midazolam demonstrated the potential for clinically significant changes in CYP3A4 activity. Such interactions are particularly relevant in mass drug administration programs where albendazole is co-administered with other anti-infectives.
Cancer therapy and personalized medicine
CYP3A4 is a major drug-metabolizing enzyme that activates or inactivates many anticancer drugs, and its activity influences personalized cancer therapy. Understanding albendazole monooxygenase activity within the broader context of CYP3A4 function may inform dosing strategies in patients receiving multiple medications. Additionally, albendazole has shown anticancer potential in preclinical studies, and its metabolism via GO:0047638 could affect its efficacy in oncology settings.
Heme-related disorders and metabolic modulation
Conditions that alter heme availability or induce heme oxygenase-1 can indirectly affect CYP3A4 activity and thus albendazole monooxygenase activity. Nitric oxide, a signaling molecule elevated in inflammation, can modulate CYP3A4 heme loading and activity, potentially impacting drug metabolism in inflammatory diseases. These links highlight the importance of considering systemic metabolic states when evaluating albendazole therapy.
From albendazole monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CYP3A4 catalyze albendazole S-oxidation? | CYP3A4 knockout HepG2 cells (KO) |
| Does a specific CYP3A4 polymorphism alter albendazole metabolism? | CYP3A4 point-mutation knock-in HEK293 cells (point mutation) |
| Can a candidate gene rescue albendazole monooxygenase activity? | CYP3A4 knock-in into a null background (knock-in) |
| Where is the enzyme localized in cells? | CYP3A4 tagged knock-in with fluorescent tag (tagged knock-in) |
| Does overexpression increase albendazole S-oxide formation? | CYP3A4 overexpression in HepG2 cells (overexpression) |
| What is the impact of METTL3 on CYP3A4 expression? | METTL3 knockout or overexpression hepatocytes (KO/overexpression) |
How to Study the albendazole monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Albendazole S-oxide formation | Quantifying monooxygenase activity in microsomes |
| RNA-seq | Transcript levels of CYP3A4 and related genes | Assessing transcriptional regulation |
| MeRIP-seq | m6A modification of CYP3A4 mRNA | Linking METTL3 to CYP3A4 expression |
| Western blot | CYP3A4 protein abundance | Validating expression changes |
| Heme assay | Heme content in cells or microsomes | Evaluating cofactor availability |
| CRISPR knockout screen | Genes affecting albendazole sensitivity | Identifying novel regulators |
| CRISPR knock-in | Tagged or mutant CYP3A4 | Localization and structure-function studies |
| Pharmacokinetic modeling | Drug exposure and interactions | Predicting clinical drug-drug interactions |
Enzyme activity assays
Direct measurement of albendazole monooxygenase activity can be performed using liver microsomes or recombinant CYP enzymes incubated with albendazole and NADPH, followed by HPLC or LC-MS quantification of albendazole S-oxide. Such assays are essential to confirm that a candidate gene product catalyzes the reaction defined by GO:0047638.
Gene expression analysis
RNA-seq and qPCR can quantify CYP3A4 and related gene expression in cells or tissues, providing insights into transcriptional regulation of albendazole monooxygenase activity. METTL3-dependent m6A modifications can be assessed by MeRIP-seq to link epitranscriptomic regulation to enzyme levels.
Proteomics and heme quantification
Mass spectrometry-based proteomics can measure CYP3A4 protein abundance, while heme quantification assays can assess cofactor availability. These methods help determine whether changes in activity are due to enzyme amount or heme loading.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens in cell lines treated with albendazole can identify genes that modulate sensitivity, revealing novel regulators of GO:0047638. Follow-up validation with targeted knockouts or knock-ins confirms causality.
How CRISPR Can Be Used to Study GO:0047638 albendazole monooxygenase activity
Knockout
CRISPR knockout of CYP3A4 in hepatic cell lines such as HepG2 or primary hepatocytes can abolish albendazole S-oxide formation, providing direct evidence that CYP3A4 is required for GO:0047638. Knockout of regulatory genes like METTL3 can reveal upstream control of CYP3A4 expression and activity.
Point Mutation
Introducing specific point mutations into CYP3A4 (e.g., active-site residues or polymorphic variants) via CRISPR base editing or HDR can test their impact on albendazole binding and catalysis. Such models help link genotype to enzyme activity and drug response.
Knock-in
Knocking in a tagged or reporter version of CYP3A4 allows real-time monitoring of enzyme localization and turnover in live cells. Knock-in of candidate genes from parasites into host cells can assess their ability to catalyze albendazole sulfoxidation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CYP3A4 can increase albendazole monooxygenase activity, enabling studies of saturation kinetics and drug-drug interactions. Overexpression models are useful for high-throughput screening of inhibitors or enhancers.
How EDITGENE Supports albendazole monooxygenase activity Research
Researchers studying albendazole monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in albendazole S-oxidation, whether a specific polymorphism alters enzyme kinetics, or whether a regulatory factor controls CYP3A4 expression. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for albendazole monooxygenase activity research.
Frequently Asked Questions About albendazole monooxygenase activity
What is albendazole monooxygenase activity?
Albendazole monooxygenase activity (GO:0047638) is the catalytic conversion of albendazole to albendazole S-oxide using NADPH and O2, as defined by QuickGO.
What genes are involved in albendazole monooxygenase activity?
The primary gene is CYP3A4, with potential contributions from CYP3A5, CYP2D6, POR and regulatory genes like METTL3 and PXR.
What is the reaction catalyzed by GO:0047638?
The reaction is: albendazole + H+ + NADPH + O2 = albendazole S-oxide + H2O + NADP+.
Which cytochrome P450 enzyme metabolizes albendazole?
CYP3A4 is the major enzyme responsible for albendazole S-oxidation, though other CYPs may contribute.
How is albendazole monooxygenase activity regulated?
It is regulated transcriptionally by PXR and METTL3, post-translationally by heme availability and nitric oxide, and by drug-drug interactions.
Why is albendazole monooxygenase activity important for drug efficacy?
It produces the active S-oxide metabolite, so changes in activity can alter anthelmintic efficacy and resistance.
Can CRISPR be used to study albendazole monooxygenase activity?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can validate candidate genes and regulatory mechanisms.
What diseases are linked to albendazole monooxygenase activity?
It is relevant to helminth infections, cystic echinococcosis, drug-drug interactions in polypharmacy, and cancer therapy where CYP3A4 metabolizes drugs.
What methods measure albendazole monooxygenase activity?
LC-MS/MS, HPLC, RNA-seq, proteomics, heme assays and CRISPR screens are commonly used.
How does METTL3 affect albendazole metabolism?
METTL3 regulates CYP3A4 expression by activating PXR translation and stabilizing CYP3A4 mRNA, thereby influencing monooxygenase activity.
Conclusion
GO:0047638 (albendazole monooxygenase activity) defines the NADPH- and O2-dependent sulfoxidation of albendazole to its active S-oxide metabolite, a reaction catalyzed primarily by CYP3A4. This activity is central to anthelmintic efficacy, drug-drug interactions and inter-individual variability in drug response. Regulatory layers including PXR, METTL3 and heme availability further modulate the enzyme's output. CRISPR-based models are powerful tools to dissect the genetic and regulatory basis of albendazole monooxygenase activity, enabling causal validation of candidate genes and informing personalized therapeutic strategies. EDITGENE's comprehensive services support researchers in building these models efficiently and rigorously.
References
- 2. Knöchel J et al.. 2024. A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.. Br J Clin Pharmacol 90(9):2180-2187 PMID: 38830622
- 3. Scott EE et al.. 2005. Structures of cytochrome P450 3A4.. Trends Biochem Sci 30(1):5-7 PMID: 15653318
- 5. Das Sinha P et al.. 2025. Nitric oxide regulates cytochrome P450 2D6 and 3A4 activity via concentration-dependent modulation of heme loading.. J Biol Chem 301(11):110772 PMID: 41022321
- 6. Wang J et al.. 2025. METTL3 regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA.. Biochem Pharmacol 239:117016 PMID: 40466953
- 7. Sevrioukova IF et al.. 2015. Anion-Dependent Stimulation of CYP3A4 Monooxygenase.. Biochemistry 54(26):4083-96 PMID: 26066995
- 8. Wang F et al.. 2023. Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.. Drug Metab Dispos 51(5):543-559 PMID: 36732076
